advanced search

Welcome: Guest

log in

Japan Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012

Publication Date May 2008
Publisher Global Markets Direct
Product Type Report
Pages 300
ISBN Number not applicable
Product Code GMD04624
Price

£1,700.00
approximately: $3,002 | €2,156

PDFBuy Now
Order above formats by FAXOrder by FAX

Summary

This report is an essential source for in-depth information and data relating to the Japan Drug Delivery Devices devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the Drug Delivery Devices in Japan

Scope

  • The report provides drug delivery devices information broken down into detailed categories and segments in Japan.
  • Total revenues, products sold, end users, and average pricing.
  • Market shares of all the key competitors.
  • Key pipeline products that are set to shape the market, broken down by sector.
  • Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
  • Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
  • Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
  • Key mergers and acquisitions, partnerships, private equity investments and IPOs.
  • Customer, hospitals and physicians data.

Reasons to buy

  • Gain a strong understanding of the drug delivery devices market in Japan.
  • Evaluate and compare the attractiveness of the market in the country.
  • Identify growth segments and opportunities in each industry sector within the country.
  • Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
  • Analyze the competitiveness of the market in the country and identify hotspots.
  • Develop strategies based on the latest product, brand, expansion and research and development news in the country.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
  • Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Content

  • 1 Table Of Contents
  • 1 Table Of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Introduction
    • 2.1 What Is This Report About?
    • 2.2 Definitions
      • 2.2.1 Drug delivery devices
  • 3 Healthcare Sector Review
    • 3.1 Healthcare Sector Review
    • 3.2 Healthcare Expenditure
    • 3.3 Healthcare Infrastructure
    • 3.4 Healthcare Policy
  • 4 Drug Delivery Devices in Japan
    • 4.1 Drug Delivery Devices Overall Revenues (2000-2012)
    • 4.2 Drug Delivery Devices Overall Volume (2000-2012)
    • 4.3 Drug Delivery Devices Company Shares (2005-2006)
  • 5 Inhalation Systems in Japan
    • 5.1 Inhalation Systems Overall Revenues (2000-2012)
      • 5.1.1 Metered Dose Inhaler Devices Overall Revenues (2000-2012)
      • 5.1.2 Dry Powder Inhaler Devices Overall Revenues (2000-2012)
    • 5.2 Inhalation Systems Overall Volume (2000-2012)
      • 5.2.1 Metered Dose Inhaler Devices Overall Volume (2000-2012)
      • 5.2.2 Dry Powder Inhaler Devices Overall Volume (2000-2012)
    • 5.3 Inhalation Systems Average Price (2000-2012)
      • 5.3.1 Metered Dose Inhaler Devices Average Price (2000-2012)
      • 5.3.2 Dry Powder Inhaler Devices Average Price (2000-2012)
    • 5.4 Inhalation Systems Distribution Share (2005-2006)
    • 5.5 Inhalation Systems Company Share (2005-2006)
  • 6 Infusion Systems in Japan
    • 6.1 Infusion Systems Overall Revenues (2000-2012)
      • 6.1.1 Infusion Disposable Sets Overall Revenue (2000-2012)
      • 6.1.2 Syringe Pumps Overall Revenue (2000-2012)
      • 6.1.3 Infusion Pumps Overall Revenues (2000-2012)
    • 6.2 Infusion Systems Overall Volume (2000-2012)
      • 6.2.1 Infusion Disposable Sets Overall Volume (2000-2012)
      • 6.2.2 Syringe Pumps Overall Volume (2000-2012)
      • 6.2.3 Infusion Pumps Overall Volume (2000-2012)
    • 6.3 Infusion Systems Average Price (2000-2012)
      • 6.3.1 Infusion Pumps Average Price (2000-2012)
      • 6.3.2 Syringe Pumps Average Price (2000-2012)
      • 6.3.3 Infusion Disposable Sets Average Price (2000-2012)
    • 6.4 Infusion Systems Distribution Share (2005-2006)
    • 6.5 Infusion Systems Company Share (2005-2006)
  • 7 Needle Free Injections in Japan
    • 7.1 Needle Free Injections Overall Revenue (2000-2012)
    • 7.2 Needle Free Injections Overall Volume (2000-2012)
    • 7.3 Needle Free Injections Average Price (2000-2012)
    • 7.4 Needle Free Injections Distribution Share (2005-2006)
    • 7.5 Needle Free Injections Company Share (2005-2006)
  • 8 AstraZeneca PLC Company Profile
    • 8.1 Company Overview
    • 8.2 Business Overview
      • 8.2.1 Products
      • 8.2.2 History
    • 8.3 Locations And Subsidiaries
    • 8.4 Financial Deals Landscape
      • 8.4.1 AstraZeneca Completes $6,900 Million Private Placement
      • 8.4.2 AstraZeneca Acquires MedImmune
      • 8.4.3 AstraZeneca Acquires Biologics Manufacturing Facility From DSM Biologics
      • 8.4.4 AstraZeneca Acquires Arrow Therapeutics
      • 8.4.5 AstraZeneca Signs An Agreement With Palatin Technologies
      • 8.4.6 AstraZeneca Signs An Agreement With Bristol-Myers Squibb
      • 8.4.7 AstraZeneca Signs An Agreement With Cubist Pharmaceuticals
      • 8.4.8 AstraZeneca Signs An Agreement With Par Pharmaceutical
      • 8.4.9 Schering Signs An Agreement With AstraZeneca
      • 8.4.10 AstraZeneca Signs An Agreement With Pozen
      • 8.4.11 AstraZeneca Signs An Agreement With Abbott
      • 8.4.12 AstraZeneca To Sell Its U.S Anaesthetic and Analgesic Product Portfolio To Abraxis BioScience
      • 8.4.13 AstraZeneca Acquires KuDOS Pharmaceuticals
      • 8.4.14 AstraZeneca Acquires A Stake In Protherics
      • 8.4.15 AstraZeneca Signs An Agreement With Targacept
      • 8.4.16 AstraZeneca Signs An Agreement With AtheroGenics
      • 8.4.17 AstraZeneca UK Signs An Agreement With Protherics
      • 8.4.18 AstraZeneca Signs An Agreement With Bayer Schering Pharma Aktiengesellschaft
      • 8.4.19 AstraZeneca Signs An Agreement With Astex Therapeutics
      • 8.4.20 AstraZeneca Signs An Agreement With Avanir Pharmaceuticals
      • 8.4.21 AstraZeneca And Royal Cosun Sells Joint Venture Advanta To Syngenta
      • 8.4.22 AstraZeneca Completes Private Placement Of $750 million
      • 8.4.23 AstraZeneca Prices EUR750 Million Private Placement
      • 8.4.24 AstraZeneca Prices Sterling Bond GBP350 Million And Euro750 Million Eurobond Private Placement
    • 8.5 Recent Developments
      • 8.5.1 Feb 22, 2008: AstraZeneca To Appeal Judgment In Alabama Medical Pricing Case
      • 8.5.2 Feb 18, 2008: AstraZeneca Appoints Non-Executive Director
      • 8.5.3 Dec 12, 2007: AstraZeneca Files Patent Infringement Actions in Response to Crestor ANDAs
      • 8.5.4 Sep 28, 2007: AstraZeneca Appoints New CFO
      • 8.5.5 Jul 25, 2007: AstraZeneca Appoints New Board Member
      • 8.5.6 Jun 06, 2007: AstraZeneca CFO Resigns
      • 8.5.7 Feb 22, 2007: AstraZeneca To Invest $120 Miilion For R&D In Macclesfield Site
      • 8.5.8 Jan 30, 2007: Philips And Leading Healthcare Companies Join For Major Research And Development
      • 8.5.9 Jan 22, 2007: AstraZeneca Makes $100 Million Research Investment In Boston
  • 9 3M Company Profile
    • 9.1 Company Overview
    • 9.2 Business Overview
      • 9.2.1 Consumer and Office
      • 9.2.2 Display and Graphics
      • 9.2.3 Electro and Communications
      • 9.2.4 Health Care
      • 9.2.5 Industrial and Transportation
      • 9.2.6 Safety, Security and Protection Services
      • 9.2.7 Products
    • 9.3 Value Chain Analysis
      • 9.3.1 Manufacturing
      • 9.3.2 Product Development
      • 9.3.3 Sales and Marketing
    • 9.4 SWOT Analysis
      • 9.4.1 3M Company Strengths
  • 3M Company Weaknesses
  • 3M Company Opportunities
  • 3M Company Threats
    • 9.5 Revenue Analysis
      • 9.5.1 Revenue by Segment
      • 9.5.2 Revenue by Geography
    • 9.6 Financial and Operational Review
      • 9.6.1 Financial Statements
      • 9.6.2 Financial Ratios
    • 9.7 Locations And Subsidiaries
    • 9.8 Financial Deals Landscape
      • 9.8.1 3M Canada Acquires Les Entreprises Solumed
      • 9.8.2 3M Acquires Bondo
      • 9.8.3 3M Acquires Lingualcare
      • 9.8.4 3M Acquires Abzil Industria E Comercio
      • 9.8.5 3M Acquires Neo Plast
      • 9.8.6 3M Acquires Assets Of DMS Chile
      • 9.8.7 3M Acquires Business Of Innovative Paper Technologies
      • 9.8.8 3M Acquires Powell
      • 9.8.9 Gen-Probe Signs An Agreement With 3M Company
      • 9.8.10 3M Acquires Acolyte Biomedica
      • 9.8.11 3M Acquires Sealed Air Corp.'S Interest In Polymask Corp
      • 9.8.12 3M Sells Its Pharmaceutical Business To Meda AB
      • 9.8.13 3M Acquires SoftMed Systems
      • 9.8.14 3M Sells its Pharmaceuticals Business to Graceway
      • 9.8.15 Gen-Probe Signs An Agreement With 3M
      • 9.8.16 3M Sells its Pharmaceutical Operations in the Asia Pacific Region to Ironbridge Capital and Archer Capital
      • 9.8.17 3M Acquires Biotrace International
      • 9.8.18 Ekahau Secures $16 Million In Additional Funding
      • 9.8.19 3M Acquires Brontes Technologies
      • 9.8.20 3M acquires Nylonge Corp
      • 9.8.21 3M Signs An Agreement With ClozeX Medical
      • 9.8.22 3M Acquires OMNII Oral Pharmaceuticals
      • 9.8.23 3M Sells Pharmaceutical Operations In The United States To Graceway
      • 9.8.24 3M Sells Pharmaceutical Business In Europe To Meda AB
      • 9.8.25 3M Sells Pharmaceutical Operations In The Asia Pacific To Ironbridge and Archer Capital
      • 9.8.26 3M Acquires Accuspray Application Technologies Inc
      • 9.8.27 3M to acquire Rochford Thompson Equipment
      • 9.8.28 3M To Acquire Aearo Technologies From Permira
      • 9.8.29 Permira To Sell Aearo Technologies To 3M
    • 9.9 Recent Developments
      • 9.9.1 Mar 31, 2008: HighJump Software Introduces Survey Management Solution for Direct Store Delivery Businesses
      • 9.9.2 Mar 24, 2008: Brazil's Companhia de Transmissao de Energia Eletrica Paulista Chooses 3M ACCR for Upgrade of Line Over Parana River in Sao Paulo State
      • 9.9.3 Mar 19, 2008: 3M to Headquarter Optical Systems Business in Asia
      • 9.9.4 Mar 19, 2008: 3M To Headquarter Optical Systems Business In North Asia
      • 9.9.5 Feb 11, 2008: 3M Increases Dividend for the 50th Straight Year
      • 9.9.6 Nov 12, 2007: 3M Declares Quarterly Dividend
      • 9.9.7 Oct 24, 2007: 3M And Sanyo Settle Suit On Lithium Ion Battery
      • 9.9.8 Aug 13, 2007: 3M Declares Quarterly Dividend
      • 9.9.9 May 08, 2007: 3M Declares Quarterly Dividend
      • 9.9.10 Apr 30, 2007: Gen-Probe And 3M Collaborate To Develop Rapid Molecular Tests
  • 10 Baxter International Company Profile
    • 10.1 Company Overview
    • 10.2 Business Overview
      • 10.2.1 BioScience
      • 10.2.2 Medication Delivery
      • 10.2.3 Renal
      • 10.2.4 Products
      • 10.2.5 History
    • 10.3 Value Chain Analysis
      • 10.3.1 Manufacturing
      • 10.3.2 Product Development
      • 10.3.3 Sales and Marketing
    • 10.4 SWOT Analysis
      • 10.4.1 Baxter International Inc. Strengths
      • 10.4.2 Baxter International Inc. Weaknesses
      • 10.4.3 Baxter International Inc. Opportunities
      • 10.4.4 Baxter International Inc. Threats
    • 10.5 Revenue Analysis
      • 10.5.1 Revenue by Segment
      • 10.5.2 Revenue by Geography
    • 10.6 Financial and Operational Review
      • 10.6.1 Financial Statements
      • 10.6.2 Financial Ratios
    • 10.7 Locations And Subsidiaries
    • 10.8 Financial Deals Landscape
      • 10.8.1 Baiyunshan And Baxter Form A Joint Venture In China
      • 10.8.2 Baxter Signs Licensing Agreement With Intercytex And Spinal Restoration
      • 10.8.3 Baxter Sells Transfusion Therapies Business to Texas Pacific and Maverick Capital
      • 10.8.4 B. Braun Acquires Renal Therapy Business Of Baxter
      • 10.8.5 Innovata signs a license agreement with Baxter International
      • 10.8.6 Kuros Biosurgery Signs An Agreement With Baxter International
      • 10.8.7 Gambro Signs An Agreement With Baxter
      • 10.8.8 Baxter Healthcare And Gambro Enter Into An Agreement
      • 10.8.9 Baxter and Cerus Enter Into Agreement With BioOne for Commercialization Of INTERCEPT Blood System
      • 10.8.10 Baxter International And Kaketsuken Enter Into Agreement
      • 10.8.11 Baxter To Acquire 40% Stake In Shanghai Baxter From Worldbest Treeful
    • 10.9 Recent Developments
      • 10.9.1 Jan 24, 2008: Baxter Achieves Record Sales and Earnings for Full-Year 2007
      • 10.9.2 Dec 18, 2007: Baxter Elects CFO
      • 10.9.3 Nov 13, 2007: Baxter Declares Quarterly Dividend
      • 10.9.4 Aug 01, 2007: Baxter Elects New Board Director
      • 10.9.5 Jul 31, 2007: Baxter Announces Quarterly Dividend
      • 10.9.6 Mar 13, 2007: Baxter Declares Additional Share Repurchase Authorization
      • 10.9.7 Feb 13, 2007: Baxter Announces Quarterly Dividend
      • 10.9.8 Nov 28, 2006: Baxter Announces Annual Dividend
      • 10.9.9 Sep 14, 2006: Baxter Appoints President, Baxter Latin America
    • 10.10 Baxter International Inc. Pipeline Products
      • 10.10.1 Next-Generation Home Hemodialysis Machine
  • 11 GlaxoSmithKline plc Company Profile
    • 11.1 Company Overview
    • 11.2 Business Overview
      • 11.2.1 Products
      • 11.2.2 History
    • 11.3 Locations And Subsidiaries
    • 11.4 Financial Deals Landscape
      • 11.4.1 GlaxoSmithKline Acquires CNS
      • 11.4.2 Bayer HealthCare Acquires Pritor Business From GlaxoSmithKline
      • 11.4.3 CNS To Merge With GlaxoSmithKline
    • 11.5 Recent Developments
      • 11.5.1 Mar 19, 2008: GSK charitable support valued at GBP282 million in 2007
      • 11.5.2 Feb 07, 2008: Full-year results announcement 2007
      • 11.5.3 Dec 19, 2007: GlaxoSmithKline And Santaris Enter Global R&D Alliance
      • 11.5.4 Dec 10, 2007: GlaxoSmithKline And OncoMed Form Strategic Alliance To Develop Cancer Stem Cell Antibody Therapeutics
      • 11.5.5 Dec 07, 2007: GlaxoSmithKline Announces Board And Management Changes
  • 12 Novartis AG Company Profile
    • 12.1 Company Overview
    • 12.2 Business Overview
      • 12.2.1 Major Products and Services
    • 12.3 Locations And Subsidiaries
    • 12.4 Financial Deals Landscape
      • 12.4.1 Bayer Schering Pharma Acquires U.S. Biologics Manufacturing Facility From Novartis
      • 12.4.2 Novartis To Acquire Majority Stake In Alcon From Nestle
      • 12.4.3 Novartis to sell Medical Nutrition business unit to Nestl
      • 12.4.4 Nestl to Acquire Novartis Medical Nutrition
      • 12.4.5 Novartis to sell its division Gerber Products Company to Nestle
  • 13 Regulation System
    • 13.1 Medical Equipment Approval Process
      • 13.1.1 Market Authorization Holder (MAH)
      • 13.1.2 Classification and Pre-Market Approval of Medical Devices
      • 13.1.3 Third Party Certification for Controlled Medical Devices
      • 13.1.4 PMDA Approval for Highly Controlled Medical Devices
      • 13.1.5 Registration Time
      • 13.1.6 Registration Fee
      • 13.1.7 Post Marketing Surveillance
      • 13.1.8 Labeling and Packaging
  • 14 Pricing and Reimbursement
    • 14.1 Market Pricing
    • 14.2 Reimbursement Policies
    • 14.3 Reimbursement Classes
      • 14.3.1 Class A
      • 14.3.2 Class B
      • 14.3.3 Class C
      • 14.3.4 Class F
    • 14.4 Request for Reimbursement
    • 14.5 Reduction in Reimbursement for Medical Devices and Drugs
  • 15 Distribution Structure
  • 16 APPENDIX
    • 16.1 Global Markets Direct Research Methodology
    • 16.2 Coverage
    • 16.3 Secondary Research
    • 16.4 Primary Research
    • 16.5 Models
    • 16.6 Forecasts
    • 16.7 Expert Panels
    • 16.8 Currency Conversion
    • 16.9 Contact Us
    • 16.10 Disclaimer
  • List of Tables
    • Table 1: Healthcare Expenditure in Japan, 2000 - 2005
    • Table 2: Number of Healthcare Institutions in Japan, 1995 - 2004
    • Table 3: Number of Hospital Beds in Japan, 1995 - 2004
    • Table 4: Number of Medical Personnel in Japan, 1995 - 2004
    • Table 5: Number of Medical Care Institutions and Beds in Japan, 2000 - 2004
    • Table 6: Drug Delivery Devices, Japan, Overall Revenues ($ mn), 2000-2012
    • Table 7: Drug Delivery Devices, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 8: Drug Delivery Devices, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 9: Drug Delivery Devices, Japan, Category Revenues ($ mn), 2000-2012
    • Table 10: Drug Delivery Devices, Japan, Category Revenues ($ mn), Historic, 2000-2007
    • Table 11: Drug Delivery Devices, Japan, Category Revenues ($ mn), Forecast, 2007-2012
    • Table 12: Drug Delivery Devices, Japan, Category Volume (Units), 2000-2012
    • Table 13: Drug Delivery Devices, Japan, Category Volume (Units), Historic, 2000-2007
    • Table 14: Drug Delivery Devices, Japan, Category Volume (Units), Forecast, 2007-2012
    • Table 15: Drug Delivery Devices, Japan, Company Share by Revenue ($ mn), 2005-2006
    • Table 16: Inhalation Systems, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 17: Inhalation Systems, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 18: Inhalation Systems, Japan, Revenue by Segment ($ mn), Historic, 2000-2007
    • Table 19: Inhalation Systems, Japan, Revenue by Segment ($ mn), Forecast, 2007-2012
    • Table 20: Metered Dose Inhaler Devices, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 21: Metered Dose Inhaler Devices, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 22: Dry Powder Inhaler Devices, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 23: Dry Powder Inhaler Devices, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 24: Inhalation Systems, Japan, Overall Volume (Units), Historic, 2000-2007
    • Table 25: Inhalation Systems, Japan, Overall Volume (Units), Forecast, 2007-2012
    • Table 26: Metered Dose Inhaler Devices, Japan, Overall Volume (Units), Historic, 2000-2007
    • Table 27: Metered Dose Inhaler Devices, Japan, Overall Volume (Units), Forecast, 2007-2012
    • Table 28: Dry Powder Inhaler Devices, Japan, Overall Volume (Units), Historic, 2000-2007
    • Table 29: Dry Powder Inhaler Devices, Japan, Overall Volume (Units), Forecast, 2007-2012
    • Table 30: Metered Dose Inhaler Devices, Japan, Average Price ($), Historic, 2000-2007
    • Table 31: Metered Dose Inhaler Devices, Japan, Average Price ($), Forecast, 2007-2012
    • Table 32: Dry Powder Inhaler Devices, Japan, Average Price ($), Historic, 2000-2007
    • Table 33: Dry Powder Inhaler Devices, Japan, Average Price ($), Forecast, 2007-2012
    • Table 34: Inhalation Systems, Japan, Distribution Share by Revenue ($ mn), 2005-2006
    • Table 35: Inhalation Systems, Japan, Company Share by Revenue ($ mn), 2005-2006
    • Table 36: Infusion Systems, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 37: Infusion Systems, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 38: Infusion Systems, Japan, Revenue by Segment ($ mn), Historic, 2000-2007
    • Table 39: Infusion Systems, Japan, Revenue by Segment ($ mn), Forecast, 2007-2012
    • Table 40: Infusion Disposable Sets, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 41: Infusion Disposable Sets, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 42: Syringe Pumps, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 43: Syringe Pumps, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 44: Infusion Pumps, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 45: Infusion Pumps, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 46: Infusion Systems, Japan, Overall Volume (Units), Historic, 2000-2007
    • Table 47: Infusion Systems, Japan, Overall Volume (Units), Forecast, 2007-2012
    • Table 48: Infusion Disposable Sets, Japan, Overall Volume (Units), Historic, 2000-2007
    • Table 49: Infusion Disposable Sets, Japan, Overall Volume (Units), Forecast, 2007-2012
    • Table 50: Syringe Pumps, Japan, Overall Volume (Units), Historic, 2000-2007
    • Table 51: Syringe Pumps, Japan, Overall Volume (Units), Forecast, 2007-2012
    • Table 52: Infusion Pumps, Japan, Overall Volume (Units), Historic, 2000-2007
    • Table 53: Infusion Pumps, Japan, Overall Volume (Units), Forecast, 2007-2012
    • Table 54: Infusion Pumps, Japan, Average Price ($), Historic, 2000-2007
    • Table 55: Infusion Pumps, Japan, Average Price ($), Forecast, 2007-2012
    • Table 56: Syringe Pumps, Japan, Average Price ($), Historic, 2000-2007
    • Table 57: Syringe Pumps, Japan, Average Price ($), Forecast, 2007-2012
    • Table 58: Infusion Disposable Sets, Japan, Average Price ($), Historic, 2000-2007
    • Table 59: Infusion Disposable Sets, Japan, Average Price ($), Forecast, 2007-2012
    • Table 60: Infusion Systems, Japan, Distribution Share by Revenue ($ mn), 2005-2006
    • Table 61: Infusion Systems, Japan, Company Share by Revenue ($ mn), 2005-2006
    • Table 62: Needle Free Injections, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 63: Needle Free Injections, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 64: Needle Free Injections, Japan, Overall Volume (Units), Historic, 2000-2007
    • Table 65: Needle Free Injections, Japan, Overall Volume (Units), Forecast, 2007-2012
    • Table 66: Needle Free Injections, Japan, Average Price ($), Historic, 2000-2007
    • Table 67: Needle Free Injections, Japan, Average Price ($), Forecast, 2007-2012
    • Table 68: Needle Free Injections, Japan, Distribution Share by Revenue ($ mn), 2005-2006
    • Table 69: Needle Free Injections, Japan, Company Share by Revenue ($ mn), 2005-2006
    • Table 70: AstraZeneca PLC, Subsidiaries
    • Table 71: 3M Company, SWOT Analysis, 2006
    • Table 72: 3M Company, Revenue by Segment, USD Million, 2003-2007
    • Table 73: 3M Company, Revenue by Geography, USD Million, 2003-2007
    • Table 74: 3M Company, Financial Statements, USD Million, 2003-2007
    • Table 75: 3M Company, Financial Ratios, USD Million, 2003-2007
    • Table 76: 3M Company, Subsidiaries
    • Table 77: Baxter International Inc., SWOT Analysis, 2006
    • Table 78: Baxter International Inc., Revenue by Segment, USD Million, 2003-2007
    • Table 79: Baxter International Inc., Revenue by Geography, USD Million, 2003-2007
    • Table 80: Baxter International Inc., Financial Statements, USD Million, 2003-2007
    • Table 81: Baxter International Inc., Financial Ratios, USD Million, 2003-2007
    • Table 82: Baxter International Inc., Other Locations
    • Table 83: Baxter International Inc., Subsidiaries
    • Table 84: GlaxoSmithKline plc, Subsidiaries
    • Table 84: GlaxoSmithKline plc, Subsidiaries(Contd..)
    • Table 85: Novartis Medical Nutrition, Other Locations
    • Table 85: Novartis Medical Nutrition, Other Locations(Contd..)
    • Table 86: Registration Processing Time for Medical Devices in Japan, 2007
    • Table 87: Product Registration Fee for Medical Devices in Japan, 2007
    • Table 88: Currency Conversion from USD to Local Currency at 2007 Constant Rate
  • List of Figures
    • Figure 1: Healthcare Expenditure in Japan, 2000 - 2005
    • Figure 2: Government and Private Healthcare Expenditure in Japan, 2005
    • Figure 3: Drug Delivery Devices, Japan, Overall Revenues ($ mn), 2000-2012
    • Figure 4: Drug Delivery Devices, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 5: Drug Delivery Devices, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 6: Drug Delivery Devices, Japan, Category Revenues ($ mn), 2000-2012
    • Figure 7: Drug Delivery Devices, Japan, Category Revenues ($ mn), Historic, 2000-2007
    • Figure 8: Drug Delivery Devices, Japan, Category Revenues ($ mn), Forecast, 2007-2012
    • Figure 9: Drug Delivery Devices, Japan, Category Volume (Units), 2000-2012
    • Figure 10: Drug Delivery Devices, Japan, Category Volume (Units), Historic, 2000-2007
    • Figure 11: Drug Delivery Devices, Japan, Category Volume (Units), Forecast, 2007-2012
    • Figure 12: Drug Delivery Devices, Japan, Company Share (%), 2006
    • Figure 13: Inhalation Systems, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 14: Inhalation Systems, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 15: Inhalation Systems, Japan, Revenue by Segment ($ mn), Historic, 2000-2007
    • Figure 16: Inhalation Systems, Japan, Revenue by Segment ($ mn), Forecast, 2007-2012
    • Figure 17: Metered Dose Inhaler Devices, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 18: Metered Dose Inhaler Devices, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 19: Dry Powder Inhaler Devices, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 20: Dry Powder Inhaler Devices, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 21: Inhalation Systems, Japan, Overall Volume (Units), Historic, 2000-2007
    • Figure 22: Inhalation Systems, Japan, Overall Volume (Units), Forecast, 2007-2012
    • Figure 23: Metered Dose Inhaler Devices, Japan, Overall Volume (Units), Historic, 2000-2007
    • Figure 24: Metered Dose Inhaler Devices, Japan, Overall Volume (Units), Forecast, 2007-2012
    • Figure 25: Dry Powder Inhaler Devices, Japan, Overall Volume (Units), Historic, 2000-2007
    • Figure 26: Dry Powder Inhaler Devices, Japan, Overall Volume (Units), Forecast, 2007-2012
    • Figure 27: Metered Dose Inhaler Devices, Japan, Average Price ($), Historic, 2000-2007
    • Figure 28: Metered Dose Inhaler Devices, Japan, Average Price ($), Forecast, 2007-2012
    • Figure 29: Dry Powder Inhaler Devices, Japan, Average Price ($), Historic, 2000-2007
    • Figure 30: Dry Powder Inhaler Devices, Japan, Average Price ($), Forecast, 2007-2012
    • Figure 31: Inhalation Systems, Japan, Distribution Share (%), 2006
    • Figure 32: Inhalation Systems, Japan, Company Share (%), 2006
    • Figure 33: Infusion Systems, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 34: Infusion Systems, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 35: Infusion Systems, Japan, Revenue by Segment ($ mn), Historic, 2000-2007
    • Figure 36: Infusion Systems, Japan, Revenue by Segment ($ mn), Forecast, 2007-2012
    • Figure 37: Infusion Disposable Sets, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 38: Infusion Disposable Sets, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 39: Syringe Pumps, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 40: Syringe Pumps, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 41: Infusion Pumps, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 42: Infusion Pumps, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 43: Infusion Disposable Sets, Japan, Overall Volume (Units), Historic, 2000-2007
    • Figure 44: Infusion Disposable Sets, Japan, Overall Volume (Units), Forecast, 2007-2012
    • Figure 45: Syringe Pumps, Japan, Overall Volume (Units), Historic, 2000-2007
    • Figure 46: Syringe Pumps, Japan, Overall Volume (Units), Forecast, 2007-2012
    • Figure 47: Infusion Pumps, Japan, Overall Volume (Units), Historic, 2000-2007
    • Figure 48: Infusion Pumps, Japan, Overall Volume (Units), Forecast, 2007-2012
    • Figure 49: Infusion Pumps, Japan, Average Price ($), Historic, 2000-2007
    • Figure 50: Infusion Pumps, Japan, Average Price ($), Forecast, 2007-2012
    • Figure 51: Syringe Pumps, Japan, Average Price ($), Historic, 2000-2007
    • Figure 52: Syringe Pumps, Japan, Average Price ($), Forecast, 2007-2012
    • Figure 53: Infusion Disposable Sets, Japan, Average Price ($), Historic, 2000-2007
    • Figure 54: Infusion Disposable Sets, Japan, Average Price ($), Forecast, 2007-2012
    • Figure 55: Infusion Systems, Japan, Distribution Share (%), 2006
    • Figure 56: Infusion Systems, Japan, Company Share (%), 2006
    • Figure 57: Needle Free Injections, Japan, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 58: Needle Free Injections, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 59: Needle Free Injections, Japan, Overall Volume (Units), Historic, 2000-2007
    • Figure 60: Needle Free Injections, Japan, Overall Volume (Units), Forecast, 2007-2012
    • Figure 61: Needle Free Injections, Japan, Average Price ($), Historic, 2000-2007
    • Figure 62: Needle Free Injections, Japan, Average Price ($), Forecast, 2007-2012
    • Figure 63: Needle Free Injections, Japan, Distribution Share (%), 2006
    • Figure 64: 3M Company, Value Chain Analysis
    • Figure 65: Baxter International Inc., Value Chain Analysis
    • Figure 66: Medical Device Classification in Japan, 2007
    • Figure 67: Approval Process for Controlled Medical Devices in Japan, 2007
    • Figure 68: Approval Process for Highly Controlled Medical Devices in Japan, 2007
    • Figure 69: Health Insurance Reimbursement Process in Japan, 2007
    • Figure 70: Distribution Structure for Medical Equipment in Japan, 2007
    • Figure 71: Global Markets Direct Methodology